Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
- - - A new 2-year comparative study from NYU Langone just droppedand the results are clear: Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide): 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat) Even in per-protocol analysis (continuous GLP-1 use), surgery still outperformed: 24.6% vs 7.6% Surgery had better HbA1c improvement, too Translational Insight: Yes, the relatively low weight loss in the medication group was partly due to therapy interruptions and discontinuation
NICE technology appraisals (TA875 for semaglutide, TA1026 for tirzepatide) restrict NHS access to adults with a BMI of 35 kg/m or above plus at least one weight-related comorbidity, within specialist services
Mild side effects like nausea or stomach upset can occur if taken in excessive amounts
However, such patients are often older and therefore likely to have some degree of vascular insufficiency, which may be apparent on a brain scan
10.1016/j.physbeh.2010.12.006 61 DossatA
GLP-1: slows stomach emptying, reduces glucagon and increases satiety (fullness)
US$ 21.16
US$ 25.06
US$ 21.27
US$ 29.59
